http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110393714-B

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-473
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D221-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-243
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-473
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-243
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D221-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
filingDate 2019-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2022-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2022-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-110393714-B
titleOfInvention A kind of antitumor drug, synthesis method and application
abstract The invention belongs to an antitumor drug, a synthetic method and application, in particular to a helicene molecule 4-aza[4]helicenium quaternary ammonium salt ([4]helicenium) drug, a synthetic method and its application in antitumor, nitrogen Hetero[4]helicene is a class of derivatives of fused-ring aromatic hydrocarbons with non-planar structure. The quaternization of aza[4]helicene can significantly increase the water solubility of the molecule and the binding ability to DNA, which can be highly efficient. It can effectively inhibit various cancers such as liver cancer, lung cancer, leukemia, etc. It is particularly noteworthy that [4]helicenium has no obvious toxicity to normal cells and tissues while killing tumor cells and tissues, and has excellent tumor selectivity. Chemotherapy-like drug-resistant tumors are also well inhibited. The [4]helicenium involved in the present invention has the advantages of simple preparation method, good water solubility and obvious curative effect on selective tumor inhibition, and has the properties of broad spectrum, high efficiency and low toxicity, and especially has wide application prospects in the field of traditional tumor chemotherapy.
priorityDate 2019-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5486532-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102850337-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6327
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425080133
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3035239
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24200453
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9136
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7840
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23939
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419530549
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID407611241
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31423
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458431511
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450298794
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454051202
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415133005
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6857599
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID74257205
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451550432
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393346
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426105809

Total number of triples: 41.